KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Recursion Pharmaceuticals (RXRX) Other Non-Current Liabilities: 2024

Historic Other Non-Current Liabilities for Recursion Pharmaceuticals (RXRX) over the last 1 years, with Dec 2024 value amounting to $4.7 million.

  • Recursion Pharmaceuticals' Other Non-Current Liabilities fell 65.69% to $1.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.0 million, marking a year-over-year decrease of 65.69%. This contributed to the annual value of $4.7 million for FY2024, which is N/A change from last year.
  • Latest data reveals that Recursion Pharmaceuticals reported Other Non-Current Liabilities of $4.7 million as of FY2024.
  • Over the past 5 years, Recursion Pharmaceuticals' Other Non-Current Liabilities peaked at $4.7 million during FY2024, and registered a low of $4.7 million during FY2024.
  • Over the past 1 years, Recursion Pharmaceuticals' median Other Non-Current Liabilities value was $4.7 million (recorded in 2024), while the average stood at $4.7 million.